Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
0.4421
-0.0079 (-1.76%)
At close: Nov 24, 2025, 4:00 PM EST
0.4500
+0.0079 (1.79%)
Pre-market: Nov 25, 2025, 7:22 AM EST

Akari Therapeutics, Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202015 - 2019
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Net Income
-15.77-19.79-10.01-17.75-17.42-17.08
Upgrade
Depreciation & Amortization
00.010000.01
Upgrade
Asset Writedown & Restructuring Costs
5.18-----
Upgrade
Stock-Based Compensation
3.682.251.150.740.310.33
Upgrade
Other Operating Activities
-3.85-1.56-6.71-5.320.24-0.15
Upgrade
Change in Accounts Payable
0.535.22-0.94-0.88-0.24-0.25
Upgrade
Change in Other Net Operating Assets
0.591.320.071.7-1.740.19
Upgrade
Operating Cash Flow
-9.65-12.55-16.43-21.5-18.85-16.95
Upgrade
Cash Acquisitions
0.380.38----
Upgrade
Investing Cash Flow
0.380.38----
Upgrade
Short-Term Debt Issued
-1.03----
Upgrade
Total Debt Issued
2.131.03----
Upgrade
Short-Term Debt Repaid
--1.86----
Upgrade
Total Debt Repaid
-1.9-1.86----
Upgrade
Net Debt Issued (Repaid)
0.22-0.83----
Upgrade
Issuance of Common Stock
9.0111.827.0225.2914.2925.07
Upgrade
Other Financing Activities
0.33-----
Upgrade
Financing Cash Flow
9.5710.997.0225.2914.2925.07
Upgrade
Foreign Exchange Rate Adjustments
0-00.010.11-0.140.2
Upgrade
Net Cash Flow
0.3-1.19-9.413.89-4.698.32
Upgrade
Free Cash Flow
-9.65-12.55-16.43-21.5-18.85-16.95
Upgrade
Free Cash Flow Per Share
-0.35-1.05-3.36-6.89-8.78-10.73
Upgrade
Levered Free Cash Flow
0.283.91-16.74-6.04-11.31-11.96
Upgrade
Unlevered Free Cash Flow
0.54.06-16.74-6.04-11.31-11.96
Upgrade
Change in Working Capital
1.126.54-0.870.82-1.98-0.06
Upgrade
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q